Open AccessSMARCA4 mutations in KRAS ‐mutant lung adenocarcinoma: a multi‐cohort analysis
Author(s) -
Liu Liang,
Ahmed Tamjeed,
Petty William J.,
Grant Stefan,
Ruiz Jimmy,
Lycan Thomas W.,
Topaloglu Umit,
Chou PingChieh,
Miller Lance D.,
Hawkins Gregory A.,
AlexanderMiller Martha A.,
O’Neill Stacey S.,
Powell Bayard L.,
D’Agostino Ralph B.,
Munden Reginald F.,
Pasche Boris,
Zhang Wei
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12831
Subject(s) - kras , smarca4 , medicine , oncology , adenocarcinoma , lung cancer , cohort , immunotherapy , cancer , biology , chromatin remodeling , gene , colorectal cancer , genetics , chromatin
In this work, we study the survival outcomes of patients with lung adenocarcinoma in four independent cohorts. By classifying patients with KRAS mutations into three subgroups based on their mutation status of TP53 and SMARCA4 , our analysis indicates that patients harboring both KRAS and SMARCA4 mutations do not benefit from the treatment with nonimmunotherapy or immune checkpoint inhibitor‐based immunotherapy. Alternative treatment strategy is requested for this subset of patients.